The mechanisms underlying the immune control of Zika virus infection at the maternal-fetal interface.

Zika virus infection inflammation maternal-fetal interface natural killer cells

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 22 07 2022
accepted: 28 10 2022
entrez: 9 12 2022
pubmed: 10 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Unlike other Flaviviruses, Zika virus (ZIKV) infection during the first trimester of pregnancy causes severe pregnancy outcomes including the devastating microcephaly and diseases associated with placental dysfunctions. We have previously reported that the maternal decidua basalis, the major maternal-fetal interface, serves as a replication platform enabling virus amplification before dissemination to the fetal compartment. However, the rate of congenital infection is quite low, suggesting the presence of a natural barrier against viral infection. Using primary cells from first-trimester pregnancy samples, we investigated in this study how the maternal decidua can interfere with ZIKV infection. Our study reveals that whether through their interactions with dNK cells, the main immune cell population of the first-trimester decidua, or their production of proinflammatory cytokines, decidual stromal cells (DSCs) are the main regulators of ZIKV infection during pregnancy. We also validate the functional role of AXL as a crucial receptor for ZIKV entry in DSCs and demonstrate that targeted inhibition of ligand-receptor interaction at the early stage of the infection is effective in drastically reducing virus pathogenesis at the maternal-fetal interface. Collectively, our results provide insights into the mechanisms through which ZIKV infection and spreading can be limited. The strategy of circumventing viral entry at the maternal-fetus interface limits virus dissemination to fetal tissues, thereby preventing congenital abnormalities.

Identifiants

pubmed: 36483552
doi: 10.3389/fimmu.2022.1000861
pmc: PMC9723234
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1000861

Informations de copyright

Copyright © 2022 Espino, Gouilly, Chen, Colin, Guerby, Izopet, Amara, Tabiasco, Al-Daccak, El Costa and Jabrane-Ferrat.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Front Immunol. 2021 Sep 24;12:718380
pubmed: 34630393
Viruses. 2019 Nov 04;11(11):
pubmed: 31690057
Viruses. 2013 Dec 30;6(1):69-88
pubmed: 24381034
Reprod Biomed Online. 2008 Feb;16(2):211-7
pubmed: 18284875
PLoS Pathog. 2017 Feb 2;13(2):e1006164
pubmed: 28152048
Annu Rev Virol. 2019 Sep 29;6(1):567-584
pubmed: 31283436
J Immunol. 2008 Sep 1;181(5):3009-17
pubmed: 18713971
Annu Rev Immunol. 2018 Apr 26;36:279-308
pubmed: 29345964
Retrovirology. 2016 Jun 06;13(1):39
pubmed: 27267272
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33393505
J Immunol. 2020 Dec 1;205(11):3083-3094
pubmed: 33139490
N Engl J Med. 2016 Mar 10;374(10):951-8
pubmed: 26862926
J Virol. 2017 Jun 26;91(14):
pubmed: 28468880
Antivir Ther. 2005;10(1):95-107
pubmed: 15751767
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):
pubmed: 34785597
Nat Rev Immunol. 2002 Sep;2(9):656-63
pubmed: 12209134
Nat Rev Immunol. 2008 Sep;8(9):713-25
pubmed: 19172692
Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents
pubmed: 11585785
Methods Mol Biol. 2022;2407:205-213
pubmed: 34985667
Immunology. 2014 Apr;141(4):490-7
pubmed: 24256296
J Reprod Immunol. 2009 Nov;82(2):142-7
pubmed: 19615756
Hepatology. 2010 Nov;52(5):1581-9
pubmed: 20812318
J Immunol. 2009 Aug 15;183(4):2610-21
pubmed: 19635919
J Clin Invest. 2014 May;124(5):1872-9
pubmed: 24789879
Nature. 1998 Feb 12;391(6668):703-7
pubmed: 9490415
Biochem Pharmacol. 2021 Jan;183:114316
pubmed: 33152343
Nat Rev Immunol. 2006 Aug;6(8):584-94
pubmed: 16868549
J Virol. 2015 Sep;89(17):8880-96
pubmed: 26085147
Front Immunol. 2019 Jun 28;10:1397
pubmed: 31379803
PLoS Pathog. 2013;9(4):e1003257
pubmed: 23592985
Nat Chem Biol. 2014 Nov;10(11):977-83
pubmed: 25242553
Sci Rep. 2016 Oct 19;6:35296
pubmed: 27759009
Nat Commun. 2020 Jun 11;11(1):2967
pubmed: 32528049
N Engl J Med. 2016 Dec 15;375(24):2321-2334
pubmed: 26943629
Cell Host Microbe. 2017 Sep 13;22(3):366-376.e3
pubmed: 28910635
Am J Reprod Immunol. 2010 Jun;63(6):434-44
pubmed: 20055791
Cell Host Microbe. 2016 Aug 10;20(2):155-66
pubmed: 27443522
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
Cell. 2020 Sep 3;182(5):1125-1139.e18
pubmed: 32822574
J Immunol. 2005 Mar 1;174(5):2878-84
pubmed: 15728498
Viral Immunol. 2020 Jan/Feb;33(1):3-11
pubmed: 31545139
Nat Immunol. 2003 Jan;4(1):87-91
pubmed: 12447359
Placenta. 1996 Nov;17(8):533-43
pubmed: 8916201
J Virol. 2006 May;80(9):4501-9
pubmed: 16611910
Front Immunol. 2021 Aug 26;12:728291
pubmed: 34512661
Cell Rep. 2017 Jan 10;18(2):324-333
pubmed: 28076778
Eur J Immunol. 2011 Oct;41(10):3017-27
pubmed: 21739430
J Immunol. 1999 Mar 15;162(6):3168-75
pubmed: 10092767
Cell Host Microbe. 2012 Oct 18;12(4):544-57
pubmed: 23084921
Curr Opin Virol. 2014 Jun;6:40-6
pubmed: 24713352
J Virol. 2019 Jul 30;93(16):
pubmed: 31142663
J Virol. 2017 Jan 31;91(4):
pubmed: 27974560
Nat Med. 2006 Sep;12(9):1065-74
pubmed: 16892062
J Immunol Res. 2015;2015:272359
pubmed: 26199948
J Immunol. 2000 Jan 15;164(2):805-11
pubmed: 10623826
J Exp Med. 2000 Oct 2;192(7):1059-68
pubmed: 11015446

Auteurs

Ana Espino (A)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Jordi Gouilly (J)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Qian Chen (Q)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Philippe Colin (P)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Paul Guerby (P)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.
Department of Obstetrics and Gynecology, Paule de Viguier Hospital, Toulouse, France.

Jacques Izopet (J)

Department of Virology, Institut Fédératif de Biologie, Toulouse, France.

Ali Amara (A)

CNRS 7212, INSERM U944, University Paris Cité, Hôpital Saint-Louis, Paris, France.

Julie Tabiasco (J)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Reem Al-Daccak (R)

INSERM UMRS976, University Paris Cité, Hôpital Saint-Louis, Paris, France.

Hicham El Costa (H)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Nabila Jabrane-Ferrat (N)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), CNRS UMR5051, INSERM UMR1291, University of Toulouse III, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH